{
  "meta": {
    "title": "47_Leukemia",
    "url": "https://brainandscalpel.vercel.app/47-leukemia-dc1ae909.html",
    "scrapedAt": "2025-11-30T06:57:21.803Z"
  },
  "questions": [
    {
      "id": 91467,
      "choices": [
        {
          "id": 288824,
          "text": "AML"
        },
        {
          "id": 288825,
          "text": "ALL"
        },
        {
          "id": 288826,
          "text": "CLL"
        },
        {
          "id": 288827,
          "text": "CML"
        }
      ],
      "text": "The peripheral smear is most likely that of a patient with ?<p><img src=\"https://d2enu63wt1sf3u.cloudfront.net/course_file_meta/279712Q.856.jpg\" alt=\"Question Image\"></p>",
      "unique_key": "Q5662037",
      "question_audio": null,
      "question_video": null,
      "map_id": 34767827,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) AML (Acute Myeloid Leukemia) Acute Myeloid Leukemia (AML) is characterized by the rapid proliferation of abnormal myeloid cells, which often results in a peripheral blood smear showing a high number of immature white blood cells, known as blasts. In AML, these blasts often appear as large cells with a high nuclear-to-cytoplasmic ratio, fine chromatin, and prominent nucleoli. The presence of these blasts, along with a reduced number of mature blood cells, is a hallmark finding in the peripheral smear of a patient with AML. Incorrect Responses: B. ALL (Acute Lymphoblastic Leukemia): While ALL also presents with a peripheral smear showing blasts, the key difference lies in the type of blasts observed. In ALL, the blasts are typically lymphoid (B-cell or T-cell), whereas in AML, the blasts are myeloid. The characteristics of lymphoid blasts (e.g., more scant cytoplasm and smaller size) differ from the myeloid blasts seen in AML, which is why the peripheral smear in ALL would look different. C. CLL (Chronic Lymphocytic Leukemia): CLL is a slow-growing leukemia that typically presents with a peripheral smear showing mature lymphocytes, often with a characteristic appearance called \"smudge cells.\" These mature lymphocytes are small with condensed chromatin and scant cytoplasm, unlike the immature, larger blasts seen in AML. D. CML (Chronic Myelogenous Leukemia): CML is characterized by an increase in mature and immature myeloid cells, but the peripheral smear shows a distinct spectrum of cells, including mature granulocytes, metamyelocytes, and myelocytes. The hallmark feature of CML is the presence of the Philadelphia chromosome and the shift towards more mature cells, unlike the predominantly blast-filled smear seen in AML.",
      "correct_choice_id": 288824,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/31235451705130976/31235451705130976.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/31235451705130976/31235451705130976.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 91468,
      "choices": [
        {
          "id": 288828,
          "text": "Cytarabine"
        },
        {
          "id": 288829,
          "text": "Daunorubicin"
        },
        {
          "id": 288830,
          "text": "ATRA"
        },
        {
          "id": 288831,
          "text": "All the above"
        }
      ],
      "text": "Name an oral drug that induces the differentiation of leukemic cells bearing the t(15;17) in AML ?",
      "unique_key": "Q3938367",
      "question_audio": null,
      "question_video": null,
      "map_id": 34626683,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) ATRA (All-Trans Retinoic Acid) All-Trans Retinoic Acid (ATRA) is an oral medication used to treat acute promyelocytic leukemia (APL), a subtype of AML that is characterized by the t(15;17) chromosomal translocation. This translocation results in the formation of the PML-RARα fusion protein, which blocks normal differentiation of myeloid cells. ATRA works by binding to the retinoic acid receptor (RARα), promoting the differentiation of leukemic promyelocytes into mature cells. This ability to induce differentiation is a hallmark of ATRA in treating APL, making it the correct answer. Incorrect Responses: A. Cytarabine: Cytarabine is a chemotherapy drug that is commonly used in the treatment of AML, but it does not specifically induce differentiation in leukemic cells. Instead, it works by inhibiting DNA synthesis, which leads to the death of rapidly dividing cells. It is not effective in inducing differentiation in APL cells with the t(15;17) translocation. B. Daunorubicin: Daunorubicin is an anthracycline chemotherapy agent used in the treatment of various types of leukemia, including AML. Like cytarabine, it works by inhibiting DNA and RNA synthesis, leading to the death of leukemic cells. However, it does not induce differentiation in leukemic cells with the t(15;17) translocation. Its action is cytotoxic, not differentiating. D. All the above: This option is incorrect because while cytarabine and daunorubicin are important drugs in the treatment of AML, they do not induce differentiation in APL cells. Only ATRA has this specific ability to induce differentiation in cells with the t(15;17) translocation.",
      "correct_choice_id": 288830,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/40801171705130990/40801171705130990.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/40801171705130990/40801171705130990.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 91469,
      "choices": [
        {
          "id": 288832,
          "text": "AML"
        },
        {
          "id": 288833,
          "text": "ALL"
        },
        {
          "id": 288834,
          "text": "CLL"
        },
        {
          "id": 288835,
          "text": "CML"
        }
      ],
      "text": "The peripheral smear is likely that of a patient with ?<p><img src=\"https://d2enu63wt1sf3u.cloudfront.net/course_file_meta/7884008Q.858.jpg\" alt=\"Question Image\"></p>",
      "unique_key": "Q2172098",
      "question_audio": null,
      "question_video": null,
      "map_id": 34581270,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) CLL (Chronic Lymphocytic Leukemia) Chronic Lymphocytic Leukemia (CLL) is characterized by a peripheral blood smear showing predominantly small, mature lymphocytes. These lymphocytes typically have a high nucleus-to-cytoplasm ratio, with dense chromatin and a scant cytoplasm. Additionally, the smear may show \"smudge cells,\" which are fragile lymphocytes that break apart during the preparation of the smear. This appearance is a hallmark of CLL, making it the most likely diagnosis based on the peripheral smear. Incorrect Responses: A. AML (Acute Myeloid Leukemia): AML typically presents with a peripheral blood smear that shows a large number of blasts—immature myeloid cells—that have a high nuclear-to-cytoplasm ratio. These blasts are much larger than the small lymphocytes seen in CLL. Additionally, AML often shows dysplastic features in the myeloid cells, which is not characteristic of CLL. B. ALL (Acute Lymphoblastic Leukemia): In ALL, the peripheral smear usually shows lymphoblasts (immature lymphocytes), which are larger than the mature lymphocytes seen in CLL. These blasts have a more prominent nucleolus and a less condensed chromatin pattern than the small, mature lymphocytes seen in CLL, distinguishing it from the CLL smear. D. CML (Chronic Myelogenous Leukemia): CML is characterized by a peripheral blood smear showing a wide spectrum of myeloid cells, ranging from mature forms like neutrophils to immature forms like myelocytes and blasts. It also often includes an elevated white blood cell count with a \"left shift.\" This is very different from the predominance of small, mature lymphocytes observed in CLL.",
      "correct_choice_id": 288834,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/565861705131006/565861705131006.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/565861705131006/565861705131006.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 91470,
      "choices": [
        {
          "id": 288836,
          "text": "Autoimmune anaemia"
        },
        {
          "id": 288837,
          "text": "Massive splenomegaly"
        },
        {
          "id": 288838,
          "text": "Massive lymphadenopathy"
        },
        {
          "id": 288839,
          "text": "All the above"
        }
      ],
      "text": "Which of the following is an indication for starting treatment in CLL?",
      "unique_key": "Q9984241",
      "question_audio": null,
      "question_video": null,
      "map_id": 34532227,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All the above Chronic Lymphocytic Leukemia (CLL) is typically managed based on symptoms and disease progression. Treatment is generally initiated when the disease causes significant clinical issues or complications. The following conditions are all indications for starting treatment in CLL: Autoimmune anemia: In CLL, autoimmune hemolytic anemia can occur when the body's immune system attacks its own red blood cells. This can lead to severe anemia, requiring treatment to control the underlying CLL and the immune response. Massive splenomegaly: Splenomegaly (enlargement of the spleen) is common in CLL and can result in significant symptoms, including pain, discomfort, and cytopenias (e.g., low red blood cells or platelets). When the spleen becomes massively enlarged and causes significant symptoms or complications, treatment is indicated. Massive lymphadenopathy: Enlarged lymph nodes are a hallmark of CLL. However, when lymphadenopathy is massive or causes symptoms such as discomfort, pain, or compression of other structures, it may warrant the initiation of therapy. Thus, all these conditions—autoimmune anemia, massive splenomegaly, and massive lymphadenopathy—are indications for starting treatment in CLL, making option D the correct answer. Incorrect Responses: A. Autoimmune anaemia: Although autoimmune anemia is an indication for treatment in CLL, it is not the only indication. Therefore, choosing only autoimmune anemia as a response would be incomplete, as the other two conditions (massive splenomegaly and lymphadenopathy) also warrant treatment initiation. B. Massive splenomegaly: While massive splenomegaly is an indication for treatment, it does not cover the full scope of reasons for starting therapy in CLL, such as autoimmune anemia and massive lymphadenopathy. Therefore, this option is incomplete. C. Massive lymphadenopathy: Like splenomegaly, massive lymphadenopathy alone is an indication for treatment but does not encompass the other possible reasons to initiate therapy, such as autoimmune anemia and massive splenomegaly.",
      "correct_choice_id": 288839,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/8759401705131018/8759401705131018.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/8759401705131018/8759401705131018.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 91471,
      "choices": [
        {
          "id": 288840,
          "text": "Rituximab"
        },
        {
          "id": 288841,
          "text": "Ofatumumab"
        },
        {
          "id": 288842,
          "text": "Obinutuzumab"
        },
        {
          "id": 288843,
          "text": "All the above"
        }
      ],
      "text": "Which of the following monoclonal antibodies can be used in the treatment of CLL ?",
      "unique_key": "Q8189799",
      "question_audio": null,
      "question_video": null,
      "map_id": 34374376,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All the above Monoclonal antibodies have become a cornerstone in the treatment of Chronic Lymphocytic Leukemia (CLL) due to their ability to target specific antigens on the surface of cancerous B cells, leading to their destruction. The following monoclonal antibodies are used in CLL treatment: Rituximab: Rituximab is a widely used monoclonal antibody that targets CD20, a protein found on the surface of B cells. It is commonly used in combination with chemotherapy for CLL treatment. Ofatumumab: Ofatumumab is another CD20-targeting monoclonal antibody. It binds to a different epitope of CD20 compared to rituximab, making it effective in patients who may not respond to rituximab. Obinutuzumab: Obinutuzumab is also a CD20-targeting monoclonal antibody, but it is engineered to have improved antibody-dependent cellular cytotoxicity (ADCC) compared to rituximab. It is used in combination with chemotherapy or as a standalone therapy in CLL. Since all three monoclonal antibodies—rituximab, ofatumumab, and obinutuzumab—are effective in treating CLL, the correct answer is D. All the above. Incorrect Responses: A. Rituximab: Rituximab is an effective treatment for CLL, but it does not fully address the fact that other monoclonal antibodies, like ofatumumab and obinutuzumab, are also used in CLL treatment. Therefore, it is incomplete to select only rituximab as the correct answer. B. Ofatumumab: Although ofatumumab is a valid treatment option for CLL, it is not the only one. Rituximab and obinutuzumab are also used in CLL therapy, so choosing only ofatumumab would not fully answer the question. C. Obinutuzumab: Similarly, while obinutuzumab is an approved therapy for CLL, it is not the only monoclonal antibody used. Rituximab and ofatumumab are also commonly used in treating CLL, making this answer incomplete.",
      "correct_choice_id": 288843,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/27928621705131032/27928621705131032.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/27928621705131032/27928621705131032.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 91472,
      "choices": [
        {
          "id": 288844,
          "text": "Adult T cell leukemia"
        },
        {
          "id": 288845,
          "text": "CML"
        },
        {
          "id": 288846,
          "text": "CLL"
        },
        {
          "id": 288847,
          "text": "MDS"
        }
      ],
      "text": "The peripheral smear shown below is most likely that of a patient with ?<p><img src=\"https://d2enu63wt1sf3u.cloudfront.net/course_file_meta/606153Q.862.jpg\" alt=\"Question Image\"></p>",
      "unique_key": "Q2066512",
      "question_audio": null,
      "question_video": null,
      "map_id": 34733395,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Adult T-cell leukemia Adult T-cell leukemia (ATLL) is a rare and aggressive leukemia caused by infection with Human T-lymphotropic virus type 1 (HTLV-1). The peripheral smear in ATLL typically shows an increased number of atypical, malignant T-cells. These T-cells may appear large, with a high nucleus-to-cytoplasm ratio, and may have irregular or \"flower-like\" nuclei. The presence of these abnormal T-cells, along with the associated clinical features, points to ATLL as the likely diagnosis in this case. Incorrect Responses: B. CML (Chronic Myelogenous Leukemia): CML is characterized by a peripheral smear showing a broad spectrum of myeloid cells, including mature forms like neutrophils, as well as intermediate forms like myelocytes and blasts. In CML, the dominant cells are myeloid (granulocytes), not T-cells, making this presentation different from ATLL. Thus, CML is an unlikely diagnosis. C. CLL (Chronic Lymphocytic Leukemia): CLL typically presents with a peripheral smear showing small, mature-appearing lymphocytes, with some smudge cells. These cells are not the large, irregularly shaped T-cells seen in ATLL. Additionally, CLL is a B-cell malignancy, not a T-cell malignancy like ATLL. D. MDS (Myelodysplastic Syndrome): MDS usually shows abnormalities in the maturation of myeloid cells, with dysplastic changes in the bone marrow and peripheral blood. The peripheral smear in MDS may show abnormal-appearing cells, such as ringed sideroblasts or hypolobulated neutrophils, but it does not typically feature the large, abnormal T-cells seen in ATLL.",
      "correct_choice_id": 288844,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/47631231705131061/47631231705131061.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/47631231705131061/47631231705131061.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 91473,
      "choices": [
        {
          "id": 288848,
          "text": "AML"
        },
        {
          "id": 288849,
          "text": "ALL"
        },
        {
          "id": 288850,
          "text": "CML"
        },
        {
          "id": 288851,
          "text": "CLL"
        }
      ],
      "text": "Richter’s transformation is a devastating complication of ?",
      "unique_key": "Q3736996",
      "question_audio": null,
      "question_video": null,
      "map_id": 34332775,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) CLL (Chronic Lymphocytic Leukemia) Richter’s transformation is a devastating complication of Chronic Lymphocytic Leukemia (CLL). It refers to the transformation of CLL into a more aggressive form of lymphoma, usually Diffuse Large B-Cell Lymphoma (DLBCL). This transformation results in a significant worsening of the disease, with patients experiencing rapid disease progression and poor prognosis. Richter's transformation occurs in a subset of patients with CLL and is associated with worse clinical outcomes, often requiring more aggressive therapy. Incorrect Responses: A. AML (Acute Myeloid Leukemia): AML is an aggressive form of leukemia involving the myeloid lineage, but it is not associated with Richter’s transformation. While AML has a poor prognosis and can undergo mutations or evolve into other forms of leukemia, it does not typically transform in the manner described in Richter’s transformation. B. ALL (Acute Lymphoblastic Leukemia): ALL is another type of leukemia, affecting immature lymphoid cells. It does not typically develop Richter’s transformation, which is specific to CLL. ALL and CLL are distinct diseases with different biological behaviors, and Richter’s transformation is not a common complication of ALL. C. CML (Chronic Myelogenous Leukemia): CML is a chronic form of leukemia characterized by the presence of the Philadelphia chromosome. While CML can undergo transformation to acute leukemia (blast crisis), this is different from Richter's transformation, which is specific to CLL.",
      "correct_choice_id": 288851,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29362321705131274/29362321705131274.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29362321705131274/29362321705131274.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 91474,
      "choices": [
        {
          "id": 288852,
          "text": "CML"
        },
        {
          "id": 288853,
          "text": "CLL"
        },
        {
          "id": 288854,
          "text": "AML"
        },
        {
          "id": 288855,
          "text": "ALL"
        }
      ],
      "text": "Rai and Binet staging is used for ?",
      "unique_key": "Q7754099",
      "question_audio": null,
      "question_video": null,
      "map_id": 34059829,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) CLL (Chronic Lymphocytic Leukemia) The Rai and Binet staging systems are specifically used to stage Chronic Lymphocytic Leukemia (CLL). These systems help assess the severity and progression of the disease based on clinical and laboratory findings. The Rai staging system is used primarily in the United States, while the Binet staging system is more commonly used in Europe. Both systems classify CLL patients into different stages based on parameters such as the extent of lymphadenopathy, organomegaly, and the level of blood lymphocytosis. These staging systems are important for determining prognosis and guiding treatment decisions. Incorrect Responses: A. CML (Chronic Myelogenous Leukemia): CML is staged using the chronic, accelerated, and blast phases rather than the Rai and Binet systems. CML is defined by the presence of the Philadelphia chromosome and is primarily assessed based on cytogenetic and molecular markers, not Rai or Binet staging. C. AML (Acute Myeloid Leukemia): AML is an aggressive form of leukemia that is typically classified using the French-American-British (FAB) classification or the WHO classification, based on the morphology of the leukemia cells and genetic mutations. Rai and Binet staging are not used for AML. D. ALL (Acute Lymphoblastic Leukemia): Similar to AML, ALL is staged based on different criteria, such as age, initial white blood cell count, and genetic markers, but the Rai and Binet systems are not applicable for staging ALL.",
      "correct_choice_id": 288853,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/77816371705131287/77816371705131287.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/77816371705131287/77816371705131287.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 91475,
      "choices": [
        {
          "id": 288856,
          "text": "Splenomegaly"
        },
        {
          "id": 288857,
          "text": "Hepatomegaly"
        },
        {
          "id": 288858,
          "text": "Lymphadenopathy"
        },
        {
          "id": 288859,
          "text": "Frontal bossing of skull"
        }
      ],
      "text": "Among the following, most common physical finding in CML patients ?",
      "unique_key": "Q3694816",
      "question_audio": null,
      "question_video": null,
      "map_id": 34345866,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Splenomegaly Splenomegaly (enlargement of the spleen) is the most common physical finding in patients with Chronic Myelogenous Leukemia (CML). It occurs in the majority of cases, especially in the chronic phase of CML, where the spleen becomes enlarged due to the accumulation of abnormal, immature white blood cells. Splenomegaly can cause discomfort or a feeling of fullness in the abdomen, and in advanced stages, it may lead to significant symptoms and complications. This is a hallmark feature of CML and is typically detected during clinical examination or imaging. Incorrect Responses: B. Hepatomegaly: While hepatomegaly (enlargement of the liver) can occur in CML, it is less common than splenomegaly. Hepatomegaly may be seen in advanced disease or in some cases of CML, but it is not as characteristic as splenomegaly. C. Lymphadenopathy: Lymphadenopathy (swelling of lymph nodes) is not typically a prominent feature in CML. While some patients with CML may develop mild lymphadenopathy, it is far less common compared to splenomegaly. Lymphadenopathy is more frequently seen in other hematologic malignancies, such as lymphomas or certain leukemias. D. Frontal bossing of skull: Frontal bossing (a prominent forehead) is generally associated with chronic myeloproliferative disorders such as polycythemia vera or conditions involving significant bone marrow expansion, but it is not a common physical finding in CML. In CML, the main clinical features are related to the spleen, blood counts, and less often bone deformities.",
      "correct_choice_id": 288856,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44606021705131301/44606021705131301.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44606021705131301/44606021705131301.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 91476,
      "choices": [
        {
          "id": 288860,
          "text": "Imatinib"
        },
        {
          "id": 288861,
          "text": "Dasatinib"
        },
        {
          "id": 288862,
          "text": "Ponatinib"
        },
        {
          "id": 288863,
          "text": "Nilotinib"
        }
      ],
      "text": "Only available BCR-ABL1 TKI active against T315I is ?",
      "unique_key": "Q6914410",
      "question_audio": null,
      "question_video": null,
      "map_id": 34516422,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Ponatinib Ponatinib is the only available BCR-ABL1 tyrosine kinase inhibitor (TKI) that is active against the T315I mutation of the BCR-ABL1 gene in Chronic Myelogenous Leukemia (CML). The T315I mutation is a well-known mutation in the BCR-ABL1 gene that confers resistance to most of the first- and second-generation TKIs, including imatinib, dasatinib, and nilotinib. Ponatinib, however, is a third-generation TKI that was specifically designed to overcome this resistance. It has demonstrated efficacy in patients with the T315I mutation, making it a critical option for patients who fail other therapies due to this mutation. Incorrect Responses: A. Imatinib: Imatinib is a first-generation TKI used to treat CML, but it is not effective against the T315I mutation. This mutation confers resistance to imatinib, which is why it is not a viable option for patients with T315I. B. Dasatinib: Dasatinib is a second-generation TKI that is more potent than imatinib and works against many resistance mutations, but it is not effective against T315I. The T315I mutation causes resistance to dasatinib, similar to imatinib, making it ineffective in patients with this specific mutation. D. Nilotinib: Nilotinib is another second-generation TKI that works well in patients with BCR-ABL1 mutations, but like dasatinib, it is also ineffective against T315I. The T315I mutation confers resistance to nilotinib, which is why it cannot be used in these patients.",
      "correct_choice_id": 288862,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/6146271705131314/6146271705131314.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/6146271705131314/6146271705131314.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}